BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Developed by a Salk Institute team, the next-generation oncolytic virus technologies licensed by IconOVir have attracted a $77 million series A round from a seasoned investor syndicate and a president and CEO fresh off a...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...its company creation and royalty deals typically range into the hundreds of millions.“We’re not typical venture investors...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...of the traditional IPO process is that venture investors...
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...on Cognition”).Investor who’s whoA wide range of venture investors...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...concept to develop a pipeline of RNA drugs,” said Habib. “We needed to bring on venture investors...
BioCentury | Aug 14, 2020
Finance

Non-European venture investment in European biotech is on the rise

...active investorsLSP topped the list of European venture investors...
BioCentury | Jul 10, 2020
Finance

With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund

...oncology and fibrosis. He added that diabetes, a key area Novo Nordisk, remains “difficult” for venture investors...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...new modalities for targeted interventions is behind the surge of interest in neurology among earlier-stage venture investors...
BioCentury | Nov 2, 2019
Finance

American Cancer Society’s BrightEdge venture fund hoping to do well by doing good

...its managing director, told BioCentury. Unlike the Cystic Fibrosis Foundation and other well-known patient group venture investors...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...While government incentives, creation of the Francis Crick Institute and the formation of new U.K.-based venture investors...
Items per page:
1 - 10 of 208
BioCentury | Jan 6, 2021
Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Developed by a Salk Institute team, the next-generation oncolytic virus technologies licensed by IconOVir have attracted a $77 million series A round from a seasoned investor syndicate and a president and CEO fresh off a...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

...its company creation and royalty deals typically range into the hundreds of millions.“We’re not typical venture investors...
BioCentury | Oct 23, 2020
Finance

SPAC to the future: an old-time IPO alternative may be back to stay

...of the traditional IPO process is that venture investors...
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...on Cognition”).Investor who’s whoA wide range of venture investors...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...concept to develop a pipeline of RNA drugs,” said Habib. “We needed to bring on venture investors...
BioCentury | Aug 14, 2020
Finance

Non-European venture investment in European biotech is on the rise

...active investorsLSP topped the list of European venture investors...
BioCentury | Jul 10, 2020
Finance

With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund

...oncology and fibrosis. He added that diabetes, a key area Novo Nordisk, remains “difficult” for venture investors...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...new modalities for targeted interventions is behind the surge of interest in neurology among earlier-stage venture investors...
BioCentury | Nov 2, 2019
Finance

American Cancer Society’s BrightEdge venture fund hoping to do well by doing good

...its managing director, told BioCentury. Unlike the Cystic Fibrosis Foundation and other well-known patient group venture investors...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...While government incentives, creation of the Francis Crick Institute and the formation of new U.K.-based venture investors...
Items per page:
1 - 10 of 208